A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Seagen Inc.
Updated on 7 October 2022
measurable disease
adult t-cell leukemia/lymphoma
peripheral t-cell lymphoma
angioimmunoblastic t-cell lymphoma
anaplastic large cell lymphoma
large cell lymphoma
t-cell leukemia


This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.

Condition Peripheral T-cell Lymphoma
Treatment cyclophosphamide, prednisone, doxorubicin, brentuximab vedotin
Clinical Study IdentifierNCT04569032
SponsorSeagen Inc.
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Newly diagnosed PTCL, excluding systemic anaplastic large cell lymphoma (sALCL), per the Revised European-American Lymphoma World Health Organization (WHO) 2016 classification
The following non-sALCL PTCL subtypes are eligible
PTCL - not otherwise specified (PTCL-NOS)
Angioimmunoblastic T-cell lymphoma (AITL)
Adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T cell leukemia virus 1)
Enteropathy-associated T-cell lymphoma (EATL)
Hepatosplenic T-cell lymphoma
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITCL)
Indolent T-cell lymphoproliferative disorder (T-LPD) of the gastrointestinal (GI) tract
Follicular T-cell lymphoma
Nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype
CD30 expression <10% by local assessment in tumor containing lymph node or other
Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT, as assessed by the site radiologist
extranodal soft tissue biopsy
An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

Exclusion Criteria

Current diagnosis of any of the following
Primary cutaneous T-cell lymphoproliferative disorders and lymphomas
Mycosis fungoides (MF), including transformed MF
History of progressive multifocal leukoencephalopathy (PML)
History of another primary invasive cancer, hematologic malignancy, or myelodysplastic
Cerebral/meningeal disease related to the underlying malignancy
syndrome that has not been in remission for at least 3 years. Exceptions are
Prior treatment with brentuximab vedotin or doxorubicin
malignancies with a negligible risk of metastasis or death (e.g., 5-year OS
Baseline peripheral neuropathy Grade 2 or higher (per the NCI CTCAE, Version 4.03) or subjects with the demyelinating form of Charcot-Marie-Tooth syndrome
≥90%), such as carcinoma in situ of the cervix, non-melanoma skin carcinoma
Left ventricular ejection fraction less than 45% or symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), or myocardial infarction within the past 6 months, or previous treatment with complete cumulative dose of >300 mg/m2 of doxorubicin
localized prostate cancer, ductal carcinoma in situ, or Stage I uterine
Any uncontrolled Grade 3 or higher (per the National Cancer Institute's Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug. Routine antimicrobial prophylaxis is permitted
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note